Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $36.50

Pacira BioSciences (NASDAQ:PCRX) had its price target increased by Royal Bank Of Canada from $25.00 to $36.50 in a report released on Friday morning,Benzinga reports. They currently have a sector perform rating on the stock.

A number of other equities research analysts also recently commented on PCRX. Weiss Ratings downgraded Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, September 16th. Leerink Partners initiated coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They set a “market perform” rating and a $28.00 price objective for the company. Jefferies Financial Group cut Pacira BioSciences from a “buy” rating to a “hold” rating and set a $36.00 target price on the stock. in a report on Thursday. HC Wainwright lowered Pacira BioSciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $38.00 to $36.50 in a research report on Friday. Finally, Oppenheimer began coverage on Pacira BioSciences in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $32.00 target price on the stock. One analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences has an average rating of “Hold” and an average price target of $33.33.

Pacira BioSciences Price Performance

PCRX stock opened at $36.31 on Friday. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $36.46. The firm has a market cap of $1.45 billion, a PE ratio of 103.75 and a beta of 0.25. The firm has a 50 day simple moving average of $25.56 and a 200 day simple moving average of $24.61. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The firm had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.74 earnings per share. Equities research analysts forecast that Pacira BioSciences will post 1.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Lauren Riker sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the sale, the senior vice president owned 62,284 shares in the company, valued at $2,262,154.88. The trade was a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the sale, the insider owned 216,384 shares of the company’s stock, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by insiders.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently modified their holdings of PCRX. Meeder Asset Management Inc. acquired a new position in shares of Pacira BioSciences in the 1st quarter valued at about $46,000. Global Retirement Partners LLC purchased a new stake in shares of Pacira BioSciences in the second quarter worth approximately $51,000. State of Wyoming purchased a new stake in shares of Pacira BioSciences in the second quarter worth approximately $78,000. PNC Financial Services Group Inc. boosted its holdings in shares of Pacira BioSciences by 15.1% during the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock worth $85,000 after purchasing an additional 492 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new stake in shares of Pacira BioSciences during the second quarter worth approximately $110,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to buy Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders a defined exit price and is expected to close by the end of 2026, subject to customary conditions. Viatris acquisition announcement
• Positive Sentiment: Viatris will add Pacira’s marketed non-opioid pain therapies, EXPAREL and ZILRETTA, along with a clinical-stage gene therapy candidate. Viatris expects the deal to expand its pain portfolio and be immediately accretive to its financial guidance metrics.
• Neutral Sentiment: RBC said a superior competing bid is unlikely, reducing the prospect of a higher offer but also lowering takeover uncertainty. The stock’s upside is therefore largely capped near the $36.50 consideration unless another bidder emerges. RBC superior bid analysis
• Neutral Sentiment: Analyst actions largely reflect the announced deal: JPMorgan upgraded PCRX to neutral, while RBC and Truist raised targets to $36.50 and maintained sector perform or hold ratings. HC Wainwright maintained neutral with a $36.50 target, and Jefferies kept hold with a $36.00 target.
• Negative Sentiment: Several shareholder-rights law firms are investigating whether Pacira’s board obtained fair value and conducted an adequate sale process. These investigations could create legal or procedural distractions, although no wrongdoing has been established. Shareholder investigation

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.